 LAVAL, Québec, Jan. 05, 2023 GLOBE NEWSWIRE -- Acasti Pharma Inc. Acasti or the Company Nasdaq: ACST and TSX-V: ACST, a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call on Tuesday, January 10, 2023 at 4:30 p.m. ET to review the recently reported preliminary topline results from two separate Phase 1 pharmacokinetic PK studies for GTX-101 and GTX-102. Both studies successfully met all target outcome measures. 